FDA approves Biogen Alzheimer’s drug, first new therapy for the disease in nearly two decades

About This Source - CNBC Television

CNBC is an American pay television business news channel, which primarily carries business day coverage of U.S. and international financial markets. Following the end of the business day and on non-trading days, CNBC primarily carries financial and business-themed documentaries and reality shows.

As of February 2015, CNBC is available to approximately 93,623,000 pay television households (80.4% of households with television) in the United States.

Recent from CNBC Television:

  • LIVE: White House press secretary Jen Psaki holds a briefing with reporters — 8/5/21
  • Robinhood options trading begins: What investors need to know
  • Amazon discloses investment in biotech firm Nautilus
  • CNBC Television published this video item, entitled “FDA approves Biogen Alzheimer’s drug, first new therapy for the disease in nearly two decades” – below is their description.

    The U.S. Food and Drug Administration just approved Biogen’s new Alzheimer’s drug Aducanumab, a historic move as it is the first new therapy for the disease in nearly two decades. The drug will be marketed under the name Aduhelm and is expected to generate billions of dollars in revenue for Biogen.

    CNBC Television YouTube Channel

    Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.

    Leave a Comment